Replies to post #977 on Fate Therapeutics Inc (FATE)

[NY1972]

Many bios including ones in China can make ipsc NK. I don't see much value there. I think it is the CAR they are interested in, Dana-Farber Cancer Institute holds the mica/b trunk patent.

[NY1972]

They shut down the FT536 trial on ovarian cancer. The GBM trial is to see the impact of mica/b CAR on CNS lesions and safety.

[NY1972]

For the OV trial just canceled, pts must have received prior bevacizumab. They want an intact BBB in GBM pts to see the impact of CAR mica/b only